BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SSGJ-627 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SSGJ-627\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07507513-53@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:SSGJ-627: Phase 2 readout est. (NCT07507513)
DESCRIPTION:SSGJ-627\, phase 2\, Ulcerative Colitis.\nStudy: The Purpose of
  This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment
  of UC\nEstimated primary completion: 28 February 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ssgj-627#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07507513
URL:https://assetmemo.bio/drug/ssgj-627#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
